A detailed history of Huntington National Bank transactions in Exelixis, Inc. stock. As of the latest transaction made, Huntington National Bank holds 394 shares of EXEL stock, worth $8,853. This represents 0.0% of its overall portfolio holdings.

Number of Shares
394
Previous 439 10.25%
Holding current value
$8,853
Previous $10,000 10.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 03, 2024

SELL
$20.17 - $23.93 $907 - $1,076
-45 Reduced 10.25%
394 $9,000
Q4 2023

Feb 07, 2024

BUY
$19.25 - $24.13 $1,540 - $1,930
80 Added 22.28%
439 $10,000
Q3 2023

Nov 08, 2023

SELL
$19.04 - $22.74 $95 - $113
-5 Reduced 1.37%
359 $7,000
Q2 2023

Aug 11, 2023

BUY
$18.17 - $20.48 $4,651 - $5,242
256 Added 237.04%
364 $6,000
Q1 2023

May 10, 2023

BUY
$16.3 - $19.41 $554 - $659
34 Added 45.95%
108 $2,000
Q4 2022

Feb 09, 2023

SELL
$14.96 - $17.39 $89 - $104
-6 Reduced 7.5%
74 $1,000
Q3 2022

Nov 07, 2022

BUY
$15.68 - $22.27 $188 - $267
12 Added 17.65%
80 $1,000
Q4 2021

Jan 21, 2022

SELL
$15.84 - $21.88 $21,621 - $29,866
-1,365 Reduced 95.25%
68 $1,000
Q3 2021

Oct 28, 2021

BUY
$16.3 - $21.14 $14,246 - $18,476
874 Added 156.35%
1,433 $30,000
Q2 2021

Jul 30, 2021

BUY
$17.95 - $25.56 $10,034 - $14,288
559 New
559 $10,000
Q3 2020

Oct 30, 2020

SELL
$20.67 - $26.94 $6,325 - $8,243
-306 Closed
0 $0
Q1 2020

Apr 27, 2020

SELL
$14.46 - $21.8 $37,899 - $57,137
-2,621 Reduced 89.55%
306 $5,000
Q4 2019

Jan 17, 2020

BUY
$15.15 - $18.89 $44,344 - $55,291
2,927 New
2,927 $52,000
Q2 2019

Jul 23, 2019

SELL
$18.93 - $24.75 $199,673 - $261,063
-10,548 Closed
0 $0
Q1 2019

Apr 09, 2019

BUY
$19.6 - $24.76 $206,740 - $261,168
10,548 New
10,548 $251,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $7.23B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Huntington National Bank Portfolio

Follow Huntington National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Huntington National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Huntington National Bank with notifications on news.